Celudex 0.1% (Ophthalmic Solution)

Indications

• Short-term treatment of inflammatory conditions of the eye
• Short-term treatment of inflammatory conditions of the ear
• Short-term treatment of inflammatory conditions of the nose

Pharmacology

• Corticosteroids bind to the glucocorticoid receptor
• Inhibits pro-inflammatory signals
• Promotes anti-inflammatory signals
• Rapidly hydrolyzed to betamethasone
• Wide therapeutic window

Dosage & Administration

• Administration via drops
• Frequency of administration based on control achieved
• Eye: 1 or 2 drops every 1 or 2 hours
• Ear: 2 or 3 drops every 2 or 3 hours
• Nose: 2 or 3 drops 2 or 3 times daily

Interaction

• Specific drug interaction studies not conducted

Side Effects

• Hypersensitivity reactions including irritation, burning, stinging, itching, dermatitis
• Corneal ulceration
• Increased intraocular pressure
• Optic nerve damage
• Reduced visual acuity
• Posterior subcapsular cataracts
• Thinning of the cornea or sclera
• Formation of posterior subcapsular cataracts
• Thinning of the globe
• Perforation of the globe
• Mydriasis
• Ptosis
• Epithelial punctate keratitis

Pregnancy & Lactation

• No adequate and well-controlled studies for pregnant women
• Should not be used extensively in pregnant women
• Unknown whether it is secreted in breast milk

Precautions & Warnings

• Not to be given for an undiagnosed red eye
• Ophthalmic treatment not to be repeated or prolonged without regular review
• Exclude raised intraocular pressure
• Exclude cataract formation
• Exclude unsuspected infections

Overdose Effects

• Long-term intensive topical use may lead to systemic effects

Therapeutic Class

• Corticosteroid

Storage Conditions

• Protect from light
• Store below 25°C
• Do not use more than 4 weeks after opening
• Keep out of reach of children

Related Brands

• Betricin 0.1% (Ophthalmic Solution) - nipa-pharmaceuticals-ltd